Revenio Group
25.74 EUR +2.06%13,944 investors are following this company
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
P/E (24e)
30.44
EV/EBIT (adj.) (24e)
22.5
P/B (24e)
6.15
Dividend yield-% (24e)
1.57 %
Target price
28.00 EUR
Recommendation
Accumulate
Updated
25.4.2024
NASDAQ Helsinki
REG1V
Daily low / high price
25.22 / 25.94
EUR
Market cap
686.77M EUR
Turnover
221.67K EUR
Volume
8.6K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Juha Kinnunen
Analyst
Latest videos
Financial calendar
Interim report
08.08.2024
Interim report
31.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
William Demant Invest A/S | 18.0 % | 18.0 % |
SEB Funds | 4.0 % | 4.0 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
John Floyd | 20.02.2024 | 22,128EUR |
Kate Taylor | 16.02.2024 | 13,820EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 61.1 | 78.8 | 97.0 | 96.6 | 105.3 | 120.9 | 141.1 | 160.9 |
growth-% | 23.4 % | 29.1 % | 23.1 % | -0.5 % | 9.1 % | 14.8 % | 16.7 % | 14.0 % |
EBITDA | 21.7 | 25.7 | 33.1 | 30.3 | 32.7 | 40.1 | 47.7 | 55.1 |
EBIT (adj.) | 19.2 | 24.5 | 30.9 | 28.5 | 29.6 | 36.8 | 44.2 | 51.2 |
EBIT | 17.1 | 22.1 | 29.7 | 26.3 | 28.6 | 35.8 | 43.3 | 50.3 |
Profit before taxes | 16.7 | 22.1 | 29.1 | 25.4 | 28.0 | 36.2 | 44.1 | 51.8 |
Net income | 13.3 | 17.3 | 21.8 | 19.1 | 21.5 | 27.8 | 34.0 | 39.9 |
EPS (adj.) | 0.58 | 0.74 | 0.86 | 0.80 | 0.85 | 1.08 | 1.31 | 1.53 |
growth-% | 22.5 % | 27.2 % | 16.9 % | -7.5 % | 5.7 % | 28.1 % | 21.3 % | 16.7 % |
Dividend | 0.32 | 0.34 | 0.36 | 0.38 | 0.40 | 0.57 | 0.72 | 0.90 |
Dividend ratio | 63.7 % | 52.4 % | 43.9 % | 52.9 % | 50.0 % | 54.0 % | 56.0 % | 60.0 % |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | 35.5 % | 32.6 % | 34.1 % | 31.4 % | 31.0 % | 33.1 % | 33.8 % | 34.3 % |
EBIT-% (adj.) | 31.4 % | 31.1 % | 31.8 % | 29.5 % | 28.1 % | 30.4 % | 31.3 % | 31.8 % |
EBIT-% | 28.0 % | 28.0 % | 30.6 % | 27.3 % | 27.2 % | 29.6 % | 30.7 % | 31.3 % |
ROE | 19.9 % | 23.4 % | 25.7 % | 20.0 % | 20.3 % | 23.2 % | 24.7 % | 25.3 % |
ROI | 17.9 % | 22.1 % | 27.6 % | 23.3 % | 23.7 % | 26.8 % | 28.8 % | 29.9 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 50.30 | 55.55 | 38.60 | 27.16 | 25.74 | 25.74 | 25.74 | 25.74 |
Shares | 26.6 | 26.7 | 26.6 | 26.6 | 26.6 | 26.6 | 26.6 | 26.6 |
Market cap | 1,336.9 | 1,482.1 | 1,026.0 | 721.9 | 684.2 | 684.2 | 684.2 | 684.2 |
Enterprise value | 1,334.9 | 1,482.0 | 1,014.6 | 718.9 | 666.1 | 646.0 | 624.2 | 599.6 |
EV/S | 21.9 | 18.8 | 10.5 | 7.4 | 6.3 | 5.3 | 4.4 | 3.7 |
EV/EBITDA | 61.5 | 57.7 | 30.6 | 23.7 | 20.4 | 16.1 | 13.1 | 10.9 |
EV/EBIT (adj.) | 69.5 | 60.4 | 32.9 | 25.2 | 22.5 | 17.6 | 14.1 | 11.7 |
EV/EBIT | 78.1 | 67.1 | 34.2 | 27.3 | 23.3 | 18.0 | 14.4 | 11.9 |
P/E (adj.) | 86.6 | 75.1 | 44.6 | 34.0 | 30.4 | 23.8 | 19.6 | 16.8 |
P/E | 100.2 | 85.7 | 47.1 | 37.8 | 31.9 | 24.6 | 20.1 | 17.1 |
P/B | 19.2 | 18.9 | 11.3 | 7.2 | 6.1 | 5.3 | 4.6 | 4.1 |
P/S | 21.9 | 18.8 | 10.6 | 7.5 | 6.5 | 5.7 | 4.8 | 4.3 |
Dividend yield | 0.6 % | 0.6 % | 0.9 % | 1.4 % | 1.6 % | 2.2 % | 2.8 % | 3.5 % |
Equity ratio | 60.9 % | 63.0 % | 66.8 % | 72.7 % | 74.2 % | 75.1 % | 75.7 % | 75.7 % |
Gearing ratio | -2.7 % | -12.5 % | -2.9 % | -16.2 % | -29.6 % | -40.7 % | -50.2 % |
Quarter data
Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24e | Q3/24e | Q4/24e | 2024e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 22.3 | 22.0 | 29.1 | 96.6 | 23.6 | 24.0 | 25.3 | 32.5 | 105.3 |
EBITDA | 5.6 | 7.1 | 10.5 | 30.3 | 6.2 | 6.5 | 8.3 | 11.6 | 32.7 |
EBIT | 4.7 | 6.0 | 9.5 | 26.3 | 5.1 | 5.5 | 7.3 | 10.6 | 28.6 |
Profit before taxes | 4.5 | 5.9 | 9.2 | 25.4 | 4.8 | 5.4 | 7.2 | 10.5 | 28.0 |
Net income | 3.3 | 4.4 | 7.1 | 19.1 | 3.6 | 4.2 | 5.5 | 8.1 | 21.5 |
ShowingAll content types
Revenio Interim Report Q1/2024
Revenio Group Corporation: Interim report January 1 –March 31, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools